Compare ASTL & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTL | OCGN |
|---|---|---|
| Founded | 1902 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 467.0M | 387.3M |
| IPO Year | N/A | 2014 |
| Metric | ASTL | OCGN |
|---|---|---|
| Price | $4.38 | $1.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 1.4M | ★ 5.0M |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | ★ 2.15% | N/A |
| EPS Growth | N/A | ★ 31.58 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4,139.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.02 | $0.52 |
| 52 Week High | $7.25 | $2.00 |
| Indicator | ASTL | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 45.21 | 48.33 |
| Support Level | $4.14 | $1.44 |
| Resistance Level | $4.64 | $1.88 |
| Average True Range (ATR) | 0.28 | 0.16 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 12.58 | 37.90 |
Algoma Steel Group Inc is a fully integrated steel producer of hot and cold rolled steel products, including coiled sheet and plate, strategically located. The firm operates in a single segment of basic steel production including sheets, plates, slabs, and freights. The company's revenue is generated from contracts to produce, ship, and deliver steel products Geographically it serves Canada, the United States, and the rest of the world, whilst driving key revenue from domestic sales. The company generates the majority of its revenue from the sale of Steel sheets and strips.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").